Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.
- Acute Coronary Syndrome
- Double-Blind Method
- Platelet Aggregation Inhibitors
- Purinergic P2 Receptor Antagonists
- Randomized Controlled Trials as Topic
- Risk Assessment
- Treatment Outcome